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Introduction
The ongoing obesity epidemic and its associated complications of chronic diseases, exert formidable challenges and burden to human health (Cheng et al. 2016 ). Obesity leads not only to an increase in adipose tissue mass, but also to the infiltration of proinflammatory cells and secretion of inflammatory cytokines. Therefore, obesity is characterized by a low-grade inflammation in local and systemic sites as demonstrated by the robust secretion of proinflammatory cytokines (e.g., IL-6), and active recruitment of leukocytes (Feng et al. 2016) .
HMGB1 is one of the most evolutionarily conserved proteins in the eukaryotic kingdom (Li et al. 2011) . It was originally identified as a chromosomal protein facilitating the binding of transcription factors to their cognate DNA sequences (Bianchi et al. 1989) . Around two decades ago, HMGB1, however, was re-discovered as an innate "danger signal" (alarmin) adopted by the innate immune system during evolution for mediating adaptive immune responses (Wang et al. 1999 ; Andersson and Tracey 2004; Izuishi et al. 2006; Barkauskaite et al. 2007; Popovic et al. 2005 ). More recently, it was interestingly noted that subjects with obesity are characterized by the increase of plasma HMGB1 levels (Giacobbe et al. 2015; Arrigo et al. 2013; Wang et al. 2015) , suggesting that HMGB1 could also be a critical player for initiating and maintaining chronic inflammatory state in adipose tissue in obesity and insulin resistance. This review intends to summarize the role of HMGB1 in the initiation and maintenance of chronic inflammation state in adipose tissue in obesity, and discuss its potential application in clinical settings.
Obesity and adipose chronic inflammation
In general, visceral adipose tissue (VAT) is considered as a site of cells and molecules to control metabolism and immune interplay relevant to energy homeostasis (Mathis 2013) . In 1993, Hotamisligil and his colleagues first noted that TNF-α mRNA and protein were elevated in adipose tissue from four different rodent models of obesity and diabetes, and blockade of TNF-α in obese fa/fa rats resulted in a significant increase of peripheral glucose uptake in response to insulin (Hotamisligil et al. 1993) , suggesting that hyperglycemia could be exacerbated by cytokine overproduction. Ten years later, two groups independently reported a marked upregulation of many inflammatory genes along with accumulation of F4/80 + macrophages in the adipose tissue of obese mice and humans (Weisberg et al. 2003; Xu et al. 2003) . These studies catalyzed the emerging notion that chronic and low-grade inflammation is a common feature in obese individuals, which serves as an underlying etiological factor for obesity-related chronic diseases such as type 2 diabetes, fat-liver disease, and cardiovascular disease (Eichelmann et al. 2016) .
Over past few years, our understanding of the mechanisms underlying obesity associated adipose inflammation has been further expanded, as more cells and molecules were discovered to M A N U S C R I P T
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4 participate in this process. In the lean state, immune cells in adipose tissues (primarily resident M2-like macrophages together with T regulatory (Treg) cells and eosinophils) synthesize IL-10, IL-4, and IL-13 to maintain an anti-inflammatory environment, through which adipose tissue maintains insulin sensitivity (Samad and Ruf 2013) . In contrast, obesity drives a shift in the number and phenotype of immune cells (Olefsky and Glass 2010; Osborn and Olefsky 2012) . Specifically, monocytes are recruited from the blood into the obese adipose tissue, where they polarize to M1 macrophages and secret proinflammatory cytokines (e.g., TNF-α, HMGB1, and IL-6) contributing to insulin resistance. Other changes accounting for the proinflammatory state include reduced numbers of eosinophils and Tregs, and elevated numbers of neutrophils, B cells, mast cells, and interferon γ-producing Th1 and CD8 + T cells (Wagner 2014) (Fig. 1) . The proinflammatory cytokines and chemokines promote inflammation and insulin resistance acting in autocrine, paracrine, and endocrine manners in adipose and other target tissues. (Lumeng 2013) . Indeed, obese WAT undergoes structural remodeling associated with an altered biochemical environment (Kammoun et al. 2014 ). In the next several sections, we discuss with focus for the implication of HMGB1 in the pathogenesis of obesity and insulin resistance.
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Hmgb1 die shortly after birth in part as a consequence of hypoglycemia (Calogero et al. 1999 ).
However, other than its nuclear role, HMGB1 has been noted to be released either passively from damaged cells, or actively secreted by cells following cellular signal transduction (Wang et al. 1999; Tsung et al. 2007; Scaffidi et al. 2002; Gardella et al. 2002) (Fig. 2) . Once in the extracellular milieu and upon interaction with its receptors, HMGB1 exerts a plethora of functions, including regulation of cell maturation, proliferation, migration, survival and death (Venereau et al. 2015) . In addition, extracellular HMGB1 was shown to act as a chemoattractant for myeloid cells (Abraham et al. 2000) , smooth muscle cells (SMCs) and meso-angioblasts, thereby promoting muscle tissue repair (Bertheloot and Latz 2017) . Interestingly, as the first critical step for its secretion from activated immune cells, its cytoplasmic translocation can be regulated by post-translational modifications such as acetylation (Bonaldi et al. 2003) , methylation and phosphorylation (Ito et al. 2007; Oh et al. 2009; Youn and Shin 2006) . For example, HMGB1 is hyperacetylated at its nuclear localization sites in monocytes and macrophages, leading to its cytosolic relocalization. Cytosolic HMGB1 is then concentrated by default into secretory lysosomes, and secreted when monocytes receive an appropriate second signal (Bonaldi et al. 2003 ). This process was recently recognized to be abrogated by pharmacological inhibition of the JAK/STAT1 pathway (Lu et al. 2014) . However, those studies on its post-translational modifications were conducted in a rather exclusive manner. It would be, therefore, necessary to clarify whether its cellular localization related post-translational modification mechanisms are in parallel or differentially modulated in a cell type-or cell activation-dependent manner (Bertheloot and Latz 2017) .
According to in vitro and in vivo studies, the immune function of HMGB1 depends on the redox forms of key cysteine residues at positions 23, 45, and 106 (Magna and Pisetsky 2016). There are three redox forms of HMGB1, including fully reduced HMGB1, disulfide HMGB1 and sulfonyl HMGB1 . Fully reduced HMGB1 without posttranslational modifications is the predominant form in the nucleus and cytoplasm under normal conditions, and it forms a heterocomplex with CXCL12 that interacts with receptor CXCR4 to promote cell migration (Venereau et al. 2013; Lian et al. 2017) . Disulfide HMGB1 with a disulfide bond connecting C23
and C45 interacts with receptor TLR4 to induce cytokine and chemokine transcription and secretion (Lian et al. 2017) . Sulfonyl HMGB1 forms after exposure to ROS and has no activity for cell migration or cytokine induction (Venereau et al. 2012) . However, the investigation of specific HMGB1 redox forms and their targeted pathways in mediating inflammation is just at its very beginning, especially in the situation of obesity. Current and upcoming projects in this field will be paving the way for future translational approaches targeting at the center of obesity-induced inflammation.
Adipocyte necrosis and HMGB1 passive release
Electron microscopy analysis revealed that in all instances, obesity-associated adipocyte death exhibits features of necrosis, including ruptured plasma membranes, dilated endoplasmic reticulum, cell debris in the extracellular space, and the appearance of small lipid droplets in the cytoplasm ( Intra-abdominal pressure in obese subjects may serve as a non-pathological factor contributing to adipocyte necrosis. Under physical condition, adipocytes in the abdominal cavity are generally subject to sudden varying pressures, as occurs for example, during cough, abdominal crunch or diverse physical exercises, and in particular, obese subjects are manifested by the higher intra-abdominal pressure (Malbrain et al. 2004; Lambert et al. 2005; Cobb et al. 2005) . A visceral adipocyte in the abdominal cavity is, thus, much more commonly exposed to rupturing forces than its siblings in subcutaneous adipose tissue (Monteiro et al. 2006) . As a matter of fact, adipocytes death occurs more frequently in visceral compared with subcutaneous fat depots (Kammoun et al. 2014 ).
Hypoxia in adipose tissue may serve as another driver of adipocyte death in the setting of obesity (Kammoun et al. 2014) . Hypoxia can activate stress pathways such as endoplasmic reticulum (ER) and oxidative stress with direct effects on adipocytes (Koumenis et al. 2002) . Large adipocytes are often presence in obese individuals, and their sizes in terms of diameters can reach up to 180µm, while the diffusion distance of oxygen is only 100-200µm (Ye et al. 2007; Goossens 2008; Helmlinger et al. 1997 ). More importantly, by employing in situ "hypoxyprobe" marker systems (such as pimonidazole) and biomarkers (e.g., leptin, plasminogen activator inhibitor type-1, matrix metalloproteinase-2, and adrenomedullin) to measure WAT hypoxia in obese mice confirmed that the hypoxic environment leads to devoid of nutrients, which prevents adipocytes to undergo energy dependent apoptosis instead of necrosis (Rausch et al. 2008; Hosogai et al. 2007; Greijer and van der Wall 2004) . Furthermore, elevated concentration of free fatty acid (FFA) may serve as a critical factor to induce adipocyte death (Rockenfeller et al. 2010; Wagner 2014) . Indeed, excessive FFA leads to mitochondria dysfunction along with accumulation of reactive oxygen species (ROS), which then induces adipocyte necrosis. Similarly, inflammatory cytokines such as TNF-α also induce adipocyte necrosis by increasing the production of ROS (Ventura et al. 2004) .
Active secretion of HMGB1 in WAT
Adipose tissue is vital for the life of mammals. Originally, adipose tissue was considered as an inert depository for excess calories in the form of lipids. It has now been well recognized that WAT also serves as an endocrine organ (Kammoun et al. 2014) . In 1994, one of the first adipocytes derived hormones, leptin, was cloned and found to be involved in the regulation of energy homeostasis (Zhang et al. 1994) . From then on, the term adipokine was used to describe any secreted substance from adipose tissue. An ever expanding number of adipokines have been discovered including more than 50 cytokines, chemokines, hormone-like factors and other mediators (Wozniak et al. 2009; Lago et al. 2009 ). More recently, HMGB1 was proposed to be an adipokine that acts as an innate pro-inflammatory mediator in WAT of patients with obesity, which may be associated with insulin resistance and metabolic syndrome (Shimizu et al. 2016) .
Gunasekaran et al. demonstrated that HMGB1 was expressed 2-fold more in adipose tissue from obese compared to normo-weight individuals, and LPS increased HMGB1 secretion by adipose-derived stem cells (ASCs), but not by adipocytes isolated from human adipose tissue . The human preadipocyte cell line SW872, can actively secrete HMGB1 (Nativel et al. 2013) . Very low level of HMGB1 release in the media could be detected in Overall, these findings indicate that HMGB1 is secreted by 3T3-L1 adipocytes, and also by the lipid-laden adipocytes in WAT of patients with obesity. However, it is yet to be well defined by which signaling pathway HMGB1 is released by adipocytes. Inactivation of JNK in adipose tissue decreased the production of HMGB1 by 30 percent, suggesting that apart from JNK, other signaling molecules are also involved in HMGB1 secretion from 3T3-L1 adipocytes (Shimizu et al. 2016) . production in adipose tissue mainly come from adipose-derived stromal cells (ASCs), which were able to respond to inflammation by increasing HMGB1 secretion in a time-dependant manner . Similarly, activation of endothelial inflammasomes due to increased free fatty acids produces HMGB1, which disrupts inter-endothelial junctions and increases paracellular permeability of endothelium contributing to early onset of endothelial injury during obesity . Visfatin is another kind of adipokine, the instigation of endothelial inflammation and increase insulin sensitivity (Winer et al. 2009; Feuerer et al. 2009 ).
Unlike its effect on macrophages and DCs, the direct impact of HMGB1 on adipocyte viability and functionality is yet to be fully addressed. Generally, necrotic adipocytes lose their membrane integrity and release HMGB1 into extracellular milieu to further impair adipocyte function, leading to obesity-associated complications such as insulin resistance and type 2 diabetes (Wagner 2014) . While those discoveries are confirmative, controversial results were also reported. Feng and colleagues reported that HMGB1 regulates autophagy in 3T3-L1 preadipocytes, and increased HMGB1 along with activated autophagy in adipose tissue of obese mice may be a protective mechanism under stressed state induced by high-fat diet (HFD) (Feng et al. 2016) . Similarly, Rocío et al. reported a positive role of HMGB1 in the regulation of β-cell secretory activity (Guzman-Ruiz et al. 2014) , but this effect could turn into detrimental in response to continuous high HMGB1 levels, as occurs in obesity. Overall, additional studies would be necessary to fully address the above observations and to dissect the underlying mechanisms.
HMGB1 signaling pathways
Currently, three putative signaling pathways (i.e., RAGE, TLR2 and TLR4) have been recognized to initiate HMGB1-mediated inflammatory responses (Park et al. 2004; He et al. 2016) (Fig. 3) .
RAGE, a member of the immunoglobulin superfamily of cell surface molecules, has ability to bind to and transduce the biological effects of advanced glycation endproducts (AGEs), which accumulate in settings such as hyperglycemia, aging, inflammation, renal failure, and oxidative stress (Lopez-Diez et al. 2016; Shekhtman et al. 2017) . Except for AGEs, RAGE is also a signal transduction receptor for non-AGE molecules such as HMGB1 (Schmidt 2017) . In adipose tissue of obese subjects, it mainly triggers nuclear factor κB (NFκB) activation, a classical inflammatory mediator (van Beijnum et al. 2008) . Of importantly note, HMGB1 binding to RAGE can upregulate RAGE signaling, which amplifies inflammation by creating a positive feedback loop (Yan et al. 1994) . Extracellular HMGB1 also contributes to IL-6 secretion through RAGE, which is one of the mediators that link obesity-derived chronic inflammation with insulin resistance (Nativel et al. 2013) . Particularly, adipose tissue contributes up to 35% of the circulating IL-6 (Nativel et al. 2013 ), which promotes low-grade inflammation to impair insulin signaling and weaken insulin sensitivity in visceral fat . As a result, administration of soluble RAGE or blocking antibody can induce a protective effect against inflammation and diabetes (Nativel et al. 2013) .
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Other than RAGE, TLR2 and 4 have also been characterized to be receptors for HMGB1. A great deal of studies have consistently demonstrated that Tlr4 deficiency decreases inflammation and insulin resistance in adipose tissue (Orr et al. 2012; Poggi et al. 2007; Tsukumo et al. 2016; Saberi et al. 2009; Tsukumo et al. 2007; Suganami et al. 2007 ). Consistently, loss of Tlr4 reduces HFD-induced hepatic steatosis and inflammation along with improved hepatic insulin sensitivity (Orr et al. 2012; Poggi et al. 2007; Saberi et al. 2009; Tsukumo et al. 2016) , and blockade of TLR4 signaling confers protection against lipid-induced insulin resistance in skeletal muscle (Holland et al. 2011; Tsukumo et al. 2016) . Similarly, TLR2 mediates FFA-induced proinflammatory response in cultured adipocytes, macrophages, and myotubes (Konner and Bruning 2011; Nguyen et al. 2007; Senn 2006) . Ablating TLR2 signaling reduces HFD-induced lipid accumulation and inflammation in the liver and adipose tissue and generally improves peripheral insulin sensitivity (Jin et al. 2013) . Similar as RAGE signaling, ligation of HMGB1 to TLR2 or TLR4 activates NFκB, which then transcribes numerous mediators such as TNF-α, IL-6
and IL-1β to promote inflammatory response in adipose tissue (Park et al. 2003; Gunasekaran et al. 2016 ).
The feasibility of HMGB1 as an early diagnostic biomarker for obesity and therapeutic target
Biomarkers are of great importance to provide valuable information for the prediction, diagnosis, and observation of the therapeutic success of common complex multi-factorial metabolic diseases such as obesity and type 2 diabetes (T2D) (Muller 2012) . Based on currently available knowledge, biomarkers used in obesity include body parameters, plasma lipids, cytokines and chemokines (Jialal et al. 2014) . Diagnosis based on these traditional biomarkers, however, usually takes place at a late stage of disease development with limited information on disease etiology (Parrizas and Novials 2016) . As obesity is an important risk factor for many metabolic diseases, knowledge about early markers may facilitate to refine prevention strategies and to provide a useful tool for the diagnosis and treatment of obesity and its complications. Therefore, only those biomarkers readily identified from easily accessible sources (e.g., blood) and associated with disease etiology could meet the demand. In this regard, serum level of HMGB1 emerges as an untapped promise.
Indeed, clinical studies demonstrated a positive correlation between HMGB1 and obesity in pregnant women, children, and Chinese subjects (Giacobbe et al. 2015; Arrigo et al. 2013; Wang et al. 2015) . Giacobbe and colleagues evaluated serum HMGB1 levels in obese pregnant women, and identified a direct and statistically significant correlation between BMI of the study group and HMGB1 levels (Giacobbe et al. 2015) . Similarly, Arrigo et al. reported a positive correlation between serum HMGB1 and obesity in children (Arrigo et al. 2013) . Independently, circulating HMGB1 was noted to be significantly increased not only in obese individuals, but also in T2D
patients . However, these studies are manifested by some limitations such as M A N U S C R I P T
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11 small example size and the lack of different ethnicities. Therefore, larger sample size coupled with different populations should be considered in the future study to further confirm the feasibility of HMGB1 as a viable biomarker for early diagnosis of obesity.
Since HMGB1 plays a critical role in obesity-induced inflammation, antagonizing HMGB1 inflammatory pathway could bring on new therapeutic targets to counteract obesity-associated pathologies. For example, neutralization of HMGB1 appears to reduce weight gain and liver inflammation in mice fed an obesogenic diet (Montes et al. 2015) . Treating apoE-deficient mice with anti-HMGB1 neutralizing antibody results in decreased lesions, as well as a reduction in many inflammatory cell types such as dendritic cells, macrophages and CD4+ T cells in atherosclerotic lesions (Kanellakis et al. 2011) . Metformin, a biguanide derivative, is the first-line drug in the treatment of type 2 diabetes (Foretz et al. 2014) . While recently, Horiuchi and colleagues, identified HMGB1 as a novel metformin-binding protein and demonstrated that metformin inhibited cytokine activity of HMGB1 in vitro and in vivo (Horiuchi et al. 2017) . This is the first report of an extracellular function of metformin that regulates inflammation induced by HMGB1, which suggests possible new ways to manage HMGB1-induced inflammation in obesity.
Conclusion remarks
Obesity has emerged as an imminent global public health concern over the past several decades. It is featured by the persistent and low-grade inflammation, and serves as a causative factor for many secondary diseases including T2D, cardiovascular disease, high cholesterol, and infertility. As an innate alarmin once released from necrotic adipocytes, HMGB1 stimulates the activation of resident immune cells in the adipose tissue. Upon activation, those resident immune cells actively secrete additional HMGB1, which then activates/recruits additional immune cells, and acts on adipocytes in autocrine, paracrine or systemic fashion. Therefore, HMGB1 plays a critical role in the initiation and maintenance of chronic inflammatory state in adipose tissue of obese subjects.
There is also feasible evidence that HMGB1 could be a viable biomarker for early diagnosis of obesity and therapeutic target for prevention and intervention of obesity-induced inflammation.
However, additional studies would be necessary to warrant its application in clinical settings. (DAMP) as well as free nucleic acid molecules from necrotic adipocytes. HMGB1 is well known to mediate RAGE, TLR2 and TLR4 activation. In addition, accumulated HMGB1 and DNA owing to increased adipocytes death and adipose tissue remodeling can be sensed by TLR9. Upon activation in this case, they mainly trigger NFκB activation to initiate the transcription of various proinflammatory cytokines including TNF-α, IL-6 and IL-1β to promote inflammation in obesity.
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Highlights:
Obesity is characterized by a chronic, low-grade inflammation in local and systemic sites. Both necrotic adipocytes and activated immune cells in adipose tissue account for the increased HMGB1 level in obese subjects. HMGB1 initiates and maintains chronic inflammatory state in adipose tissue through RAGE, TLR2 and TLR4 signaling pathways. HMGB1 could be a viable biomarker for early diagnosis of obesity and therapeutic target for prevention and intervention of obesity-induced inflammation.
